IAA Journal of Applied Sciences 14(1):115-118, 2026. www.iaajournals.org

©IAAJOURNALS ISSN: 2636-7246

https://doi.org/10.59298/IAAJAS/2026/141115118 IAAJAS: 141000

CRISPR-Based Gene Drive Technology for Anopheles Mosquito Population Suppression in Malaria Control

Twesigye Davis

Department of Pharmacognosy Kampala International University Uganda
Email: twesigyedavis@studwc.kiu.ac.ug

ABSTRACT

Malaria, primarily transmitted by Anopheles mosquitoes, continued to exact a heavy toll worldwide. Traditional vector control methods face challenges such as insecticide resistance, necessitating novel, sustainable interventions. CRISPR-based gene drive technology offers a revolutionary approach by promoting the spread of genetic modifications through mosquito populations to suppress or modify them, aiming to disrupt malaria transmission. This review critically examined the development, molecular mechanisms, experimental validation, clinical implications, and translational prospects of CRISPR-based gene drives for Anopheles mosquito population suppression as a malaria control strategy. A comprehensive literature review was conducted, analyzing recent peer-reviewed articles, experimental data, and modeling studies on CRISPR gene drives targeting Anopheles vectors. CRISPR-Cas9 gene drives efficiently bias inheritance to propagate fertility-reducing traits, achieving high transmission rates in laboratory mosquitoes with potential population suppression. Modeling predicts substantial malaria transmission reduction following successful field implementation. However, challenges included resistance allele formation, ecological risks, ethical concerns, and governance complexities. Advances in molecular design, containment strategies, and stakeholder engagement are essential to address these issues. CRISPR gene drive technology represented a transformative, yet complex, tool for malaria vector control with the promise of significant transmission interruption. Responsible development integrating rigorous scientific, ecological, and ethical considerations is crucial to harness its full potential in high-transmission settings.

Keywords: CRISPR, Gene drive, Anopheles mosquito, Malaria control, Population suppression.

INTRODUCTION

Malaria remains a pervasive global health burden, especially in sub-Saharan Africa, where Anopheles mosquitoes serve as the primary vectors for Plasmodium falciparum transmission [1, 2]. Conventional control methods such as insecticide-treated nets, indoor residual spraying, and antimalarial drugs have achieved notable successes but are increasingly undermined by insecticide resistance and behavioral adaptations of mosquito vectors. These limitations motivate exploration of innovative vector control strategies, including genetic modifications designed to suppress mosquito populations or render them refractory to parasite development.

Gene drive systems are genetic engineering technologies that bias inheritance to rapidly spread desired traits through wild populations, offering a potentially transformative approach for vector control. CRISPR-Cas9-based gene drives facilitate precise genome editing, enabling the introduction of traits such as reduced fertility, pathogen resistance, or population suppression [3, 4]. Laboratory and contained field trial evidence demonstrate the feasibility of such approaches in Anopheles gambiae, the dominant malaria vector in Africa. However, translating gene drive technology into real-world malaria control programs requires addressing ecological, ethical, and technical considerations, including gene flow, resistance development, and regulatory frameworks [5].

This review critically appraises the molecular basis of CRISPR gene drives, evaluates current experimental and modeling evidence, discusses translational potential with emphasis on population suppression, and highlights controversies, biosafety concerns, and future research directions necessary for responsible deployment.

Molecular Mechanism and Biochemical Foundations

CRISPR-Cas9 gene drive constructs operate by encoding a nuclease (Cas9) and a guide RNA (gRNA) targeting a specific genomic locus, typically a gene essential for female fertility or parasite development. When introduced into mosquitoes, the gene drive cassette integrates into the homologous chromosome, and during meiosis, Cas9 induces a double-strand break in the wild-type allele. The cell repairs this break via homology-directed repair (HDR), copying the cassette onto the homologous chromosome, thereby converting heterozygotes into homozygotes—preferentially transmitting the drive allele [6].

This biased inheritance results in super-Mendelian propagation, enabling rapid dissemination of the desired trait across populations. The biochemical efficiency hinges on the precise cleavage activity of Cas9, the fidelity of gRNA binding to target sequences, and the balance between HDR and non-homologous end joining (NHEJ), which can generate resistance alleles [7–9]. Engineering constructs to improve homing efficiency and minimize resistance has been central to advancing this technology. Furthermore, anti-resistance strategies include targeting conserved genomic regions, multiplexing gRNAs, and deploying reversal drives [10].

However, biochemical limitations persist, such as off-target effects, incomplete drives, and resistance emergence, which threaten the stability and safety of gene drive systems. Current molecular efforts focus on optimizing Cas9 variants, refining gRNA design, and incorporating fail-safe or reversal mechanisms to mitigate ecological risks [11].

Analytical and Experimental Approaches

Experimental validation of gene drives involves laboratory cage trials assessing allele inheritance, population suppression efficacy, and resistance dynamics. Recent studies report successful drive propagation in laboratory colonies of Anopheles gambiae, with some constructs achieving over 95% inheritance rates across multiple generations. These novel constructs utilize Cas9 variants with enhanced activity and multiplexed gRNAs, addressing resistance development [12].

Mathematical modeling complements empirical data, projecting drive behavior in complex ecological settings. Models incorporate parameters such as drive efficiency, fitness costs, resistance allele formation, and migration to predict spread and suppression outcomes. Simulations suggest that high-fidelity drives can achieve local eradication of targeted populations if release ratios are sufficient and resistance is minimal. However, models also highlight the potential for resistance evolution and ecological rebound, emphasizing the need for empirical validation and environmental risk assessments [13].

Assessing biosafety and containment protocols remains crucial during laboratory research, with confined cage experiments and stakeholder engagement guiding responsible development [14].

Clinical and Pathophysiological Implications

While gene drive technology primarily aims at vector population suppression, its ultimate clinical impact depends on preventing human-mosquito-parasite transmission. Effective suppression of Anopheles populations would drastically reduce P. falciparum incidence, morbidity, and mortality. Modeling studies project potential reductions in malaria prevalence exceeding 80% in areas with high mosquito densities, provided gene drives are successfully deployed [15].

Additionally, the ecological consequences of mosquito suppression are a critical consideration. Potential effects on ecosystems such as impacts on predator-prey dynamics and biodiversity must be evaluated through field trials and ecological studies. The risk of unintended consequences, such as gene flow to non-target species or disruption of local ecosystems, necessitates rigorous monitoring and adaptive management strategies [16].

From a pathophysiological perspective, reducing vector populations could decrease human exposure to infectious bites, thereby reducing transmission intensity and parasite prevalence, ultimately alleviating disease burden at a population level. Nonetheless, the complex interplay among ecological, genetic, and socio-cultural factors warrants comprehensive risk assessments before large-scale deployment.

Therapeutic and Translational Aspects

Gene drive technology exemplifies a translational convergence of molecular genetics, ecology, and public health. Progress from laboratory demonstrations to field trials requires iterative refinement of drive constructs, resistance management, and delivery strategies. The development of self-limiting or reversal drives offers avenues for controllability and mitigation of ecological risks [17].

Biosafety and governance frameworks are integral to translation, emphasizing stakeholder engagement, consent, and regulatory oversight by national and international bodies. Recent pilot studies in semi-contained settings demonstrate the technical feasibility of gene drive releases, but broader implementation hinges on public acceptance and ethical considerations [18].

In addition, integrating gene drives with conventional control measures such as insecticide-treated nets and antimalarial drugs is essential to maximize efficacy. Research into eco-evolutionary dynamics informs strategies to prevent resistance and sustain suppression effects [19]. Ongoing advances in genomic editing, ecological modeling, and community engagement are critical to translating laboratory success into ethically responsible, effective malaria control interventions.

Gaps, Controversies, and Future Research Directions

Despite promising results, many scientific, ecological, and ethical gaps hamper field deployment. Resistance evolution remains a significant challenge, as drive-resistant alleles can rapidly undermine suppression efforts. Additionally, ecological effects, including the impact on non-target species, food webs, and genetic diversity, are poorly understood, necessitating long-term ecological studies [20].

Controversies surrounding the potential for gene drives to alter ecosystems or cross borders fuel public and stakeholder resistance. Regulatory frameworks are still emerging, with calls for transparent, inclusive decision-making processes involving local communities, scientists, and policymakers [21].

Future research must prioritize the development of reversible and localized drives, resistance management strategies, and ecological monitoring protocols. Technical refinements such as multiplexed gRNAs, improved Cas9 variants, and minimal off-target effects are essential. Ethical considerations, including consent and environmental justice, should underpin all stages of development to ensure socially responsible implementation. Multidisciplinary collaborations are imperative to address these multifaceted challenges and realize the potential of gene drives as sustainable malaria control tools.

CONCLUSION

CRISPR-based gene drive technology harbors transformative potential for malaria vector control by enabling rapid suppression of Anopheles populations in endemic regions. Empirical evidence demonstrates high efficacy in laboratory settings, with promising initial results from field-like experiments proposing sustained population suppression. Nonetheless, ecological safety, resistance management, ethical approval, and governance frameworks remain as critical hurdles that must be rigorously addressed. The ability to contain and reverse gene drives may mitigate some risks; however, comprehensive ecological and social assessments are essential. Successful implementation requires a coordinated effort involving scientific innovation, transparent ethical discourse, regulatory oversight, and community engagement. While the promise of gene drives is substantial, cautious progression supported by robust empirical and ecological data will determine their role in future malaria eradication strategies. Invest in multidisciplinary research to refine gene drive containment, reversibility, and ecological impact assessment, ensuring ethically responsible deployment tailored to specific regional contexts.

REFERENCES

1. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
2. Ainebyoona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.C., Uti, D.E., Alum, B.N, Echegu, D.A. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication (2025). Ethiopian Journal of Health Sciences, 2025; 35(3): 205-217. doi: 10.4314/ejhs.v35i3.9. PMID: 40717722; PMCID: PMC12287706.
3. Zhao, Y., Li, L., Wei, L., Wang, Y., Han, Z.: Advancements and Future Prospects of CRISPR-Cas-Based Population Replacement Strategies in Insect Pest Management. Insects 2024, Vol. 15, Page 653. 15, 653 (2024). https://doi.org/10.3390/INSECTS15090653
4. Nateghi Rostami, M.: CRISPR/Cas9 gene drive technology to control transmission of vector-borne parasitic infections. Parasite Immunol. 42, e12762 (2020). https://doi.org/10.1111/PIM.12762
5. Osei-Tutu, L., Kariuki, S.K., Lee, C.K., Fabre, R., Bii, D.K., Adjei, S., Oneko, M., Attobrah Sarfo, M.A., Ockenhouse, C.F., Schuerman, L., Buabeng, P.B.Y., Bakari, A., Atieno, C., Kotoh-Mortty, M.F., Otieno, K., Ntiamoah, Y., Sang, T., Bollaerts, A., Westercamp, N., Ansong, D., Agbenyega, T., Samuels, A.M., Ofori-Anyinam, O.: Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial. Lancet Glob Health. 13, e1723–e1736 (2025). https://doi.org/10.1016/S2214-109X(25)00272-4
6. Haine, V., Oneko, M., Debois, M., Ndeketa, L., Agyapong, P.D., Boahen, O., Harrison, S.B.E., Adeniji, E., Kaali, S., Kayan, K., Owusu-Agyei, S., French, N., Kariuki, S., Devadiga, R., Ogutu, B., Ansah, N.A., Orsini, M., Ansah, P.O., Maleta, K., Ong'echa, J.M., Phiri, V.K., Mzanga, P., Jere, T.M., Azongo, D.K., Mategula, D., Orimbo, J., Oduro, A.R., Otieno, W., Kaburise, M.B., Ababio, L.O., Sifuna, P.M., Amoit, S.K., Olewe, F., Oyieko, J.N., Achieng Oguk, E., Guerra Mendoza, Y., Awuni, D., Sing'oei, V., Onyango, I., Schuerman, L., Ochieng, B.O., Okoth, G.O., Nyangulu, W., Cherop, R.Y., Odera-Ojwang, P., Cravcenco, C., Chipatala, R., Roman, F., Savic, M., Asante, K.P.: Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study. Lancet Glob Health. 13, e995–e1005 (2025). https://doi.org/10.1016/S2214-109X(25)00096-8
7. Alum, E.U.: Career Advancement towards Nascent Technologies: RNA in Focus. IDOSR JOURNAL OF SCIENTIFIC RESEARCH. 9, 49–53 (2024). https://doi.org/10.59298/IDOSRJSR/2024/9.2.4953.100

8. Aja, P.M., Agu, P.C., Ogbu, C., Alum, E.U., Fasogbon, I.V., Musyoka, A.M., Ngwueche, W., Egwu, C.O., Tusubira, D., Ross, K.: RNA research for drug discovery: Recent advances and critical insight. Gene. 947, 149342 (2025). https://doi.org/10.1016/J.GENE.2025.149342
9. Leal, A.F.;, Herreno-Pachón, A.M.;, Benincore-Flórez, E.;, Karunathilaka, A.;, Tomatsu, S., Leal, A.F., María Herreno-Pachón, A., Benincore-Flórez, E., Karunathilaka, A., Tomatsu, S.: Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches. International Journal of Molecular Sciences 2024, Vol. 25, Page 2456. 25, 2456 (2024). https://doi.org/10.3390/IJMS25052456
10. Zoa, J.A., Njemguie Linjouom, R.M., Nyangono Ndongo, M., Nkeck, J.R.: Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials. PLOS Global Public Health. 5, e0004387 (2025). https://doi.org/10.1371/JOURNAL.PGPH.0004387
11. Malaria vaccines (RTS,S and R21), https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
12. Hill, J., Bange, T., Hoyt, J., Kariuki, S., Jalloh, M.F., Webster, J., Okello, G.: Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective. Lancet Glob Health. 12, e672–e684 (2024). https://doi.org/10.1016/S2214-109X(24)00013-5
13. Osoro, C.B., Ochodo, E., Kwambai, T.K., Otieno, J.A., Were, L., Sagam, C.K., Owino, E.J., Kariuki, S., ter Kuile, F.O., Hill, J.: Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. BMJ Glob Health. 9, e014719 (2024). https://doi.org/10.1136/BMJGH-2023-014719
14. Kelly, S.L., Malinga, J., Penny, M.A., Nawaz, S., Thompson, H., Gordon, S., Winskill, P., Hogan, A., Mulongeni, P., Verity, B., Ghani, A.: Comparing modelled impact and cost-effectiveness estimates for the RTS,S/AS01 malaria vaccine with evaluation results observed in phased pilot introductions PATH, Seattle, USA EXECUTIVE SUMMARY Overall assessment.
15. Björkman, A., Benn, C.S., Aaby, P., Schapira, A.: RTS,S/AS01 malaria vaccine—proven safe and effective? Lancet Infect Dis. 23, e318–e322 (2023). https://doi.org/10.1016/S1473-3099(23)00126-3
16. Yihunie, W., Abebe, D., Kebede, B., Tegegne, B.A., Getachew, M., Aschale, Y., Belew, H., Bahiru, B.: Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults. Clin Pharmacol. 15, 21–32 (2023). https://doi.org/10.2147/CPAA.S400155
17. Dimala, C.A., Kika, B.T., Kadia, B.M., Blencowe, H.: Current challenges and proposed solutions to the effective implementation of the RTS, S/ AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review. PLoS One. 13, (2018). https://doi.org/10.1371/JOURNAL.PONE.0209744
18. Aleshnick, M., Florez-Cuadros, M., Martinson, T., Wilder, B.K.: Monoclonal antibodies for malaria prevention. Molecular Therapy. 30, 1810 (2022). https://doi.org/10.1016/J.YMTHE.2022.04.001
19. World Health Organization: Monoclonal antibodies for malaria prevention: preferred product characteristics and clinical development considerations. (2023)
20. Skinner, J., Kayentao, K., Ongoiba, A., Healy, S.A., Hu, Z., Preston, A.C., Niangaly, A., Schwabl, P., Cisse, H., Doumbo, S., Doumtabe, D., Traore, A., Li, S., Peterson, M.E., Seilie, A.M., Chavtur, C., Staubus, W., Chang, M., Kelley, K., Traore, H., Djiguiba, A., Keita, M., Ouattara, A., Doucoure, M., Keita, M., Diarra, D., Sylla, M., Diakite, D., Konate, M., Traore, S., Zéguimé, A., Dolo, A., Neafsey, D.E., Murphy, S.C., Traore, B., Seder, R.A., Crompton, P.D.: Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial. Nat Med. 31, 2682–2690 (2025). https://doi.org/10.1038/S41591-025-03739-Y;SUBJMETA
21. Kayentao, K., Ongoiba, A., Preston, A.C., Healy, S.A., Doumbo, S., Doumtabe, D., Traore, A., Traore, H., Djiguiba, A., Li, S., Peterson, M.E., Telscher, S., Idris, A.H., Kisalu, N.K., Carlton, K., Serebryannyy, L., Narpala, S., McDermott, A.B., Gaudinski, M., Traore, S., Cisse, H., Keita, M., Skinner, J., Hu, Z., Zéguimé, A., Ouattara, A., Doucoure, M., Dolo, A., Djimdé, A., Traore, B., Seder, R.A., Crompton, P.D.: Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. New England Journal of Medicine. 387, 1833–1842 (2022). https://doi.org/10.1056/NEJMOA2206966

CITE AS: Twesigye Davis (2026). CRISPR-Based Gene Drive Technology for Anopheles Mosquito Population Suppression in Malaria Control. IAA Journal of Applied Sciences 14(1):115-118. https://doi.org/10.59298/IAAJAS/2026/141115118